AU2009255305B2 - Monoclonal antibodies to basic fibroblast growth factor - Google Patents
Monoclonal antibodies to basic fibroblast growth factor Download PDFInfo
- Publication number
- AU2009255305B2 AU2009255305B2 AU2009255305A AU2009255305A AU2009255305B2 AU 2009255305 B2 AU2009255305 B2 AU 2009255305B2 AU 2009255305 A AU2009255305 A AU 2009255305A AU 2009255305 A AU2009255305 A AU 2009255305A AU 2009255305 B2 AU2009255305 B2 AU 2009255305B2
- Authority
- AU
- Australia
- Prior art keywords
- fgf2
- mab
- antibody
- gal
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5718308P | 2008-05-29 | 2008-05-29 | |
| US61/057,183 | 2008-05-29 | ||
| US17056109P | 2009-04-17 | 2009-04-17 | |
| US61/170,561 | 2009-04-17 | ||
| PCT/US2009/045519 WO2009148928A1 (en) | 2008-05-29 | 2009-05-28 | Monoclonal antibodies to basic fibroblast growth factor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009255305A1 AU2009255305A1 (en) | 2009-12-10 |
| AU2009255305B2 true AU2009255305B2 (en) | 2014-10-30 |
Family
ID=41398450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009255305A Ceased AU2009255305B2 (en) | 2008-05-29 | 2009-05-28 | Monoclonal antibodies to basic fibroblast growth factor |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8101725B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2288717B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5972573B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101590495B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102046803B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009255305B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0912035A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2725873C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2633297T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010012616A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009148928A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101590495B1 (ko) | 2008-05-29 | 2016-02-01 | 갤럭시 바이오테크, 엘엘씨 | 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체 |
| WO2013134414A1 (en) * | 2012-03-06 | 2013-09-12 | Galaxy Biotech, Llc | Bispecific antibodies with an fgf2 binding domain |
| JP2016510751A (ja) | 2013-03-06 | 2016-04-11 | ジェネンテック, インコーポレイテッド | 抗がん剤耐性を治療及び予防する方法 |
| US9415118B2 (en) | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
| US9498532B2 (en) * | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| WO2015191986A1 (en) | 2014-06-13 | 2015-12-17 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| CN104231079A (zh) * | 2014-09-12 | 2014-12-24 | 暨南大学 | 一种靶向bFGF高亲和力受体结合位点的抗体及其应用 |
| PL238516B1 (pl) | 2016-06-13 | 2021-08-30 | Univ Wroclawski | Sposób otrzymywania modyfikowanego polipeptydu |
| IL266769B2 (en) * | 2016-11-22 | 2024-04-01 | Merck Patent Gmbh | Monoclonal antibodies specific for fgfr1 and their preparation |
| TW202229343A (zh) | 2020-08-21 | 2022-08-01 | 美商健臻公司 | Fgfr3抗體及使用方法 |
| CN115869397B (zh) * | 2022-08-31 | 2026-03-20 | 暨南大学 | Fgf-2纳米抗体在制备治疗银屑病药物中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU6605690A (en) | 1989-10-27 | 1991-05-31 | Du Pont Merck Pharmaceutical Company, The | Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| WO2000046380A2 (en) * | 1999-02-08 | 2000-08-10 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| IL139380A0 (en) * | 2000-10-31 | 2001-11-25 | Prochon Biotech Ltd | Active variants of fibroblast growth factor |
| EP1476120B1 (en) * | 2002-02-21 | 2010-09-29 | Duke University | Treatment methods using anti-cd22 antibodies |
| US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
| US7560244B2 (en) * | 2003-06-04 | 2009-07-14 | Joslin Diabetes Center, Inc. | Method of evaluating a subject for risk or predisposition of reduced renal function over time |
| EA015363B1 (ru) | 2003-07-18 | 2011-06-30 | Эмджен Инк. | Агенты, специфически связывающие фактор роста гепатоцитов, и их применение |
| JP3904578B2 (ja) | 2005-04-08 | 2007-04-11 | シャープ株式会社 | 半導体装置の製造方法 |
| RU2007146986A (ru) * | 2005-06-02 | 2009-06-27 | ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи (US) | Способы лечения опухолей головного мозга с использованием антител |
| AR059922A1 (es) | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| US7649083B2 (en) | 2006-06-02 | 2010-01-19 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding antibody |
| MX2008015138A (es) | 2006-06-02 | 2009-01-28 | Aveo Pharmaceuticals Inc | Proteinas de union al factor de crecimiento de hepatocitos (fch). |
| KR101590495B1 (ko) | 2008-05-29 | 2016-02-01 | 갤럭시 바이오테크, 엘엘씨 | 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체 |
-
2009
- 2009-05-28 KR KR1020107029136A patent/KR101590495B1/ko not_active Expired - Fee Related
- 2009-05-28 ES ES09759089.7T patent/ES2633297T3/es active Active
- 2009-05-28 MX MX2010012616A patent/MX2010012616A/es active IP Right Grant
- 2009-05-28 CA CA2725873A patent/CA2725873C/en not_active Expired - Fee Related
- 2009-05-28 US US12/474,198 patent/US8101725B2/en not_active Expired - Fee Related
- 2009-05-28 EP EP09759089.7A patent/EP2288717B1/en not_active Revoked
- 2009-05-28 CN CN200980119682.5A patent/CN102046803B/zh not_active Expired - Fee Related
- 2009-05-28 WO PCT/US2009/045519 patent/WO2009148928A1/en not_active Ceased
- 2009-05-28 JP JP2011511828A patent/JP5972573B2/ja not_active Expired - Fee Related
- 2009-05-28 BR BRPI0912035A patent/BRPI0912035A2/pt not_active Application Discontinuation
- 2009-05-28 AU AU2009255305A patent/AU2009255305B2/en not_active Ceased
-
2011
- 2011-12-15 US US13/327,624 patent/US20130209482A1/en not_active Abandoned
-
2015
- 2015-05-06 JP JP2015094533A patent/JP2016006034A/ja active Pending
Non-Patent Citations (2)
| Title |
|---|
| OGASAWARA S. et al., "Expressions of Basic Fibroblast Growth Factor and Its Receptors and Their Relationship to Proliferation of Human Hepatocellular Carcinoma Cell Lines", Hepatology, 1996, Vol. 24, No. 1, pages 198-205 * |
| TAKAHASHI et al., Federation of European Biochemical Societies, August 1991, Vol. 288, No. 1-2, pages 65-71 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2633297T3 (es) | 2017-09-20 |
| CN102046803A (zh) | 2011-05-04 |
| KR20110011710A (ko) | 2011-02-08 |
| EP2288717A4 (en) | 2012-08-15 |
| JP2011521966A (ja) | 2011-07-28 |
| US20090304707A1 (en) | 2009-12-10 |
| MX2010012616A (es) | 2010-12-21 |
| CN102046803B (zh) | 2014-09-17 |
| BRPI0912035A2 (pt) | 2017-05-23 |
| US8101725B2 (en) | 2012-01-24 |
| WO2009148928A1 (en) | 2009-12-10 |
| AU2009255305A1 (en) | 2009-12-10 |
| KR101590495B1 (ko) | 2016-02-01 |
| JP5972573B2 (ja) | 2016-08-17 |
| EP2288717A1 (en) | 2011-03-02 |
| EP2288717B1 (en) | 2017-07-05 |
| US20130209482A1 (en) | 2013-08-15 |
| CA2725873C (en) | 2018-05-01 |
| JP2016006034A (ja) | 2016-01-14 |
| CA2725873A1 (en) | 2009-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230242650A1 (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 | |
| US8101725B2 (en) | Monoclonal antibodies to basic fibroblast growth factor | |
| US20150110788A1 (en) | Bispecific antibodies with an fgf2 binding domain | |
| HK40045902A (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 | |
| HK1207974B (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 | |
| HK1160012B (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |